Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) has seen an increase of nearly 4%, currently trading at 13.76 HKD, following the announcement of an enhanced global strategic collaboration with AstraZeneca, focusing on the development of next-generation biotherapies including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] Group 1: Strategic Collaboration - HAPO Pharmaceutical has announced an update to its global strategic collaboration with AstraZeneca established in March 2025 [1] - The collaboration will leverage both companies' expertise to jointly discover and develop new biotherapies [1] - AstraZeneca will nominate R&D projects annually for the next four years, highlighting the deepening partnership [1] Group 2: Financial Terms - HAPO Pharmaceutical will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1] - The economic terms are consistent with the financial framework agreed upon in March 2025 [1]

Core Viewpoint - Heptagon Pharmaceuticals (02142) has announced an update to its global strategic collaboration with AstraZeneca, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] Group 1: Collaboration Details - The collaboration will see AstraZeneca nominate R&D projects to Heptagon Pharmaceuticals annually over the next four years, highlighting the deepening partnership [1] - Heptagon Pharmaceuticals will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1] - The economic terms of this collaboration align with the financial framework established in March 2025 [1] Group 2: Market Reaction - Heptagon Pharmaceuticals' stock rose nearly 4% in the afternoon session, with a current increase of 3.15%, trading at HKD 13.76, and a transaction volume of HKD 33.4244 million [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 100,000 shares at a total cost of HKD 1.337 million [1] - The buyback price per share ranges from HKD 13.18 to HKD 13.53 [1]

Group 1 - The company, He Bo Pharmaceutical-B (02142.HK), announced a share buyback on November 28, spending HKD 1.34 million to repurchase 100,000 shares [1]

Core Viewpoint - The company, HAPO Pharmaceutical-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 100,000 shares at a total cost of HKD 1.337 million [1] - The buyback price per share ranges from HKD 13.18 to HKD 13.53 [1] - The buyback is scheduled for November 28, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年11月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包 ...

Core Viewpoint - Heptagon Pharmaceuticals-B (02142.HK) has seen a price increase of over 4%, currently trading at 14.22 HKD with a transaction volume of 27.84 million HKD [2] Summary by Category - **Stock Performance** - Heptagon Pharmaceuticals-B's stock rose by 4.25% [2] - The current trading price is 14.22 HKD [2] - The transaction volume reached 27.84 million HKD [2]

Core Viewpoint - Heptagon Pharmaceuticals (02142) has seen a stock increase of over 4%, currently trading at 14.22 HKD, with a transaction volume of 27.84 million HKD, following the announcement of an updated global strategic collaboration with AstraZeneca established in March 2025 [1] Group 1: Collaboration Details - The collaboration aims to jointly discover and develop next-generation biotherapies, including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] - AstraZeneca will nominate R&D projects annually for the next four years, highlighting the deepening partnership between the two companies [1] - Heptagon Pharmaceuticals is eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of the licensed projects, consistent with the financial framework established in March 2025 [1]

Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) has increased by over 4%, reaching HKD 14.22, with a trading volume of HKD 27.84 million, following the announcement of an updated global strategic collaboration with AstraZeneca [1] Group 1: Collaboration Details - HAPO Pharmaceutical announced an update to its global strategic collaboration with AstraZeneca, established in March 2025, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] - Under the agreement, AstraZeneca will nominate R&D projects annually for the next four years, demonstrating the deepening of the partnership [1] - HAPO Pharmaceutical will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of the licensed projects, consistent with the financial framework established in March 2025 [1]

Core Insights - The announcement highlights the deepening global strategic collaboration between Heptares Therapeutics and AstraZeneca established in March 2025 [1] - The partnership focuses on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] Collaboration Details - AstraZeneca will nominate research projects to Heptares Therapeutics annually over the next four years, demonstrating the ongoing commitment to the partnership [1] - Heptares Therapeutics is eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1]